+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Cancer Biomarkers Market Size, Share & Industry Trends Analysis Report By Profiling Technologies, By Application, By Type, By Cancer Type, By Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 121 Pages
  • April 2022
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5600809
The Asia Pacific Cancer Biomarkers Market is expected to witness market growth of 17.8% CAGR during the forecast period (2022-2028).

The utilization of RNA, DNA, microRNAs, and proteins in cancer detection involves molecular changes. To lessen the physical and emotional impact of cancer on patients and their families, governments in various nations are focused on investing in cancer prevention and early intervention. Additionally, governmental healthcare departments are actively involved in cancer research and therapy development. The rising incidence of cancer is predicted to spur innovation and advancement in the field of biomarker-based cancer diagnostics.

Due to an increase in the occurrence of different types of cancer such as prostate, breast, and lung cancer, the worldwide cancer biomarkers Market is predicted to develop significantly over the forecast period. Additionally, the rising importance of biological and targeted medicinal therapies, technical improvements, and the precision and reliability of cancer biomarkers all contribute to the Market 's growth. Additionally, increased government and public-private sector investments in cancer diagnostics R&D have a favorable impact on the industry. The cancer biomarkers Market is expected to benefit from advances in cancer research and a substantial unfulfilled need for cancer diagnostics.

The Asia Pacific witnessed increased usage of biomarker-based tests for cancer detection and the deployment of technologically sophisticated instruments by laboratories in the area.  Additionally, increased funding and investments from public and private organizations in biomarker research and development, as well as the use of biomarkers in patient stratification and the medication development process, are expected to propel the Market in the area forward.

One of the top causes of death in Asian countries is cancer. In addition, the National Cancer Centre reported that three forms of blood malignancies (multiple lymphoma, malignant myeloma, and leukemia) accounted for some share of all cancers in Japan. After the United States and China, India has the world's third-highest number of blood cancer sufferers. The cancer rate has risen dramatically in recent decades and is anticipated to continue to rise substantially during the prediction period. Other important Market drivers include a more efficient drug delivery mechanism, non-invasive technologies, and higher survival rates. On the other side, the Market is hampered by the significant cost of diagnosis & products, reimbursement concerns, and the necessity for quick processing.

The China Market dominated the Asia Pacific Cancer Biomarkers Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $2,797 million by 2028. The Japan Market is experiencing a CAGR of 17.1% during (2022-2028). Additionally, The India Market is expected to exhibit CAGR of 18.6% during (2022-2028).

Based on Profiling Technologies, the Market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, and Cytogenetics. Based on Application, the Market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Others. Based on Type, the Market is segmented into Protein, Genetic, and Others. Based on Cancer Type, the Market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma & Leukemia, Kidney & Bladder Cancer, Non-Hodgkin's Lymphoma, Prostate Cancer, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.

Scope of the Study


Market Segments Covered in the Report:


By Profiling Technologies
  • Omics Technologies
  • Imaging Technologies
  • Immunoassay
  • Bioinformatics
  • Cytogenetics
By Application
  • Diagnostics
  • Research & Development
  • Prognostics
  • Risk Assessment
  • Others
By Type
  • Protein
  • Genetic
  • Others
By Cancer Type
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Thyroid Cancer
  • Melanoma & Leukemia
  • Kidney & Bladder Cancer
  • Non-Hodgkin's Lymphoma
  • Prostate Cancer
  • Others

By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players


List of Companies Profiled in the Report:

  • BioMérieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Merck & Co., Inc.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Cancer Biomarkers Market, by Profiling Technologies
1.4.2 Asia Pacific Cancer Biomarkers Market, by Application
1.4.3 Asia Pacific Cancer Biomarkers Market, by Type
1.4.4 Asia Pacific Cancer Biomarkers Market, by Cancer Type
1.4.5 Asia Pacific Cancer Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Cancer Biomarkers Market
Chapter 4. Asia Pacific Cancer Biomarkers Market by Profiling Technologies
4.1 Asia Pacific Omics Technologies Market by Country
4.2 Asia Pacific Imaging Technologies Market by Country
4.3 Asia Pacific Immunoassay Market by Country
4.4 Asia Pacific Bioinformatics Market by Country
4.5 Asia Pacific Cytogenetics Market by Country
Chapter 5. Asia Pacific Cancer Biomarkers Market by Application
5.1 Asia Pacific Diagnostics Market by Country
5.2 Asia Pacific Research & Development Market by Country
5.3 Asia Pacific Prognostics Market by Country
5.4 Asia Pacific Risk Assessment Market by Country
5.5 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Cancer Biomarkers Market by Type
6.1 Asia Pacific Protein Market by Country
6.2 Asia Pacific Genetic Market by Country
6.3 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Cancer Biomarkers Market by Cancer Type
7.1 Asia Pacific Breast Cancer Market by Country
7.2 Asia Pacific Lung Cancer Market by Country
7.3 Asia Pacific Colorectal Cancer Market by Country
7.4 Asia Pacific Thyroid Cancer Market by Country
7.5 Asia Pacific Melanoma & Leukemia Market by Country
7.6 Asia Pacific Kidney & Bladder Cancer Market by Country
7.7 Asia Pacific Non-Hodgkin's Lymphoma Market by Country
7.8 Asia Pacific Prostate Cancer Market by Country
7.9 Asia Pacific Others Market by Country
Chapter 8. Asia Pacific Cancer Biomarkers Market by Country
8.1 China Cancer Biomarkers Market
8.1.1 China Cancer Biomarkers Market by Profiling Technologies
8.1.2 China Cancer Biomarkers Market by Application
8.1.3 China Cancer Biomarkers Market by Type
8.1.4 China Cancer Biomarkers Market by Cancer Type
8.2 Japan Cancer Biomarkers Market
8.2.1 Japan Cancer Biomarkers Market by Profiling Technologies
8.2.2 Japan Cancer Biomarkers Market by Application
8.2.3 Japan Cancer Biomarkers Market by Type
8.2.4 Japan Cancer Biomarkers Market by Cancer Type
8.3 India Cancer Biomarkers Market
8.3.1 India Cancer Biomarkers Market by Profiling Technologies
8.3.2 India Cancer Biomarkers Market by Application
8.3.3 India Cancer Biomarkers Market by Type
8.3.4 India Cancer Biomarkers Market by Cancer Type
8.4 South Korea Cancer Biomarkers Market
8.4.1 South Korea Cancer Biomarkers Market by Profiling Technologies
8.4.2 South Korea Cancer Biomarkers Market by Application
8.4.3 South Korea Cancer Biomarkers Market by Type
8.4.4 South Korea Cancer Biomarkers Market by Cancer Type
8.5 Singapore Cancer Biomarkers Market
8.5.1 Singapore Cancer Biomarkers Market by Profiling Technologies
8.5.2 Singapore Cancer Biomarkers Market by Application
8.5.3 Singapore Cancer Biomarkers Market by Type
8.5.4 Singapore Cancer Biomarkers Market by Cancer Type
8.6 Malaysia Cancer Biomarkers Market
8.6.1 Malaysia Cancer Biomarkers Market by Profiling Technologies
8.6.2 Malaysia Cancer Biomarkers Market by Application
8.6.3 Malaysia Cancer Biomarkers Market by Type
8.6.4 Malaysia Cancer Biomarkers Market by Cancer Type
8.7 Rest of Asia Pacific Cancer Biomarkers Market
8.7.1 Rest of Asia Pacific Cancer Biomarkers Market by Profiling Technologies
8.7.2 Rest of Asia Pacific Cancer Biomarkers Market by Application
8.7.3 Rest of Asia Pacific Cancer Biomarkers Market by Type
8.7.4 Rest of Asia Pacific Cancer Biomarkers Market by Cancer Type
Chapter 9. Company Profiles
9.1 BioMérieux S.A.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.3 Becton, Dickinson and Company
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Abbott Laboratories
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Thermo Fisher Scientific, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.6 SWOT Analysis
9.6 Illumina, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.7 Bio-Rad laboratories, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Qiagen N.V.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Product Launches and Product Expansions:
9.9 Agilent Technologies, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.10. Merck & Co., Inc. (Merck Millipore)
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses

Companies Mentioned

  • BioMérieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Merck & Co., Inc.

Methodology

Loading
LOADING...